• 1
    Landi MT, Sinha R, Lang NP, Kadlubar FF. Human cytochrome P4501A2. In Metabolic Polymorphisms and Susceptibility to Cancer. ed RyderW. Lyon: IARC. Scientific Publications no. 148, 1999: 173195.
  • 2
    Butler MA, Iwasaki M, Guengerich FP, Kadlubar FF. Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 1989; 0: 76967700.
  • 3
    Bock KW, Schrenk D, Forster A, et al. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics 1994; 4: 209218.
  • 4
    Lampe JW, King IB, Li S, et al. Brassica vegetables increase and apiaceous vegetables decrease cytochrome P450 1A2 activity in humans: changes in caffeine metabolite ratios in response to controlled vegetable diets. Carcinogenesis 2000; 21: 11571162.
  • 5
    Rost KL, Roots I. Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios. Coincidence with plasma clearance and breath test. Clin Pharmacol Ther 1994; 55: 402411.
  • 6
    Fuhr U, Anders EM, Mahr G, Sorgel F, Staib AH. Inhibitory potency of quinolone antibacterial agents against cytochrome P4501A2 activity in vivo and in vitro. Antimicrob Agents Chemother 1992; 36: 942948.
  • 7
    Nakajima M, Yokoi T, Mizutani M, Knoshita M, Funayama M, Kamataki T. Genetic polymorphism in the 5’-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem 1999; 125: 803808.
  • 8
    Sachse C, Brockmöller J, Bauer S, Roots I. Functional significance of a C[RIGHTWARDS ARROW]A polymorphism in intron I of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999; 47: 445449.
  • 9
    Rasmussen BB, Brix TH, Kyvik KO, Brøsen K. The interindividual differencees in the 3-demethylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics 2002; 12: 473478.
  • 10
    Kalow W, Tang BK. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther 1991; 50: 508519.
  • 11
    Streetman DS, Bertino JS, Jr Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 2000; 10: 187216.
  • 12
    Tantcheva-Poór I, Zaigler M, Rietbrock S, Fuhr U. Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. Pharmacogenetics 1999; 9: 131144.
  • 13
    Facciolá G, Hidestrand M, Von Bahr C, Tybring G. Cytochrome P450 isoforms involved in melatonin metabolism in human liver microsomes. Eur J Clin Pharmacol 2001; 56: 881888.
  • 14
    Härtter S, Ursing C, Morita S, et al. Orally given melatonin may serve as a probe drug for CYP1A2 activity in vivo. Clin Pharmacol Ther 2001; 70: 1016.
  • 15
    Christensen M, Andersson K, Dalen P, et al. The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin Pharmacol Ther 2003; 73: 517528.
  • 16
    English J, Middleton BA, Arendt J, Wirz-Justice A. Rapid direct measurement of melatonin in saliva using an iodinated tracer and solid phase second antibody. Ann Clin Biochem 1993; 30: 415416.
  • 17
    Nordmark A, Lundgren S, Ask B, Granath F, Rane A. The effect of CYP1A2*1F on CYP 1A2 inducibility in pregnant women. Br J Clin Pharmacol 2002; 54: 504510.
  • 18
    Härtter S, Grözinger M, Weigmann H, Röschke J, Hiemke C. Increased bioavailability of oral melatonin after fluvoxamine coadministration. Clin Pharmacol Ther 2000; 67: 16.
  • 19
    Hameleers PAHM, Van Boxtel MPJ, Hogervorst E, et al. Habitual caffeine consumption and its relation to memory, attention, planning capacity and psychomotor performance across multiple age groups. Hum Psychopharmacol Clin Exp 2000; 15: 573581.